Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery—A Humanitarian Cause DOI Open Access
Sarfaraz K. Niazi,

Matthias Magoola

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12797 - 12797

Published: Nov. 28, 2024

Recombinant therapeutic and vaccine proteins have revolutionized healthcare, but there remain challenges, as many are awaiting development due to their slow speed high cost. Cell-free in vivo ribosomes offer one choice, they come with similar constraints. The validation of messenger RNA (mRNA) technology has been accomplished for COVID-19 vaccines. bioreactors inside the body, ribosomes, deliver these at a small cost, since chemical products do not require extensive analytical regulatory exercises. In this study, we test validate final product. A smaller fraction recombinant protein cost is needed, removing both Although thousands mRNA under development, classification remains unresolved: qualify drugs, biological drug, or gene therapy items? These questions will soon be resolved. Additionally, how would copies approved brought in, treated: new generic drugs? Researchers currently working answer questions. Regardless, products’ goods (COGs) much than that ex products. This necessary meet needs approximately 6.5 billion people around world who access drugs; indeed serve dire humanity. Given minor establishing manufacturing products, it also prove financially attractive investors.

Language: Английский

Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands DOI
Florian Zeevat, Simon van der Pol, Tjalke A. Westra

et al.

Advances in Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 10, 2025

Language: Английский

Citations

1
Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs DOI

Darvin Scott Smith,

Maarten J. Postma, David N. Fisman

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 51, P. 126879 - 126879

Published: Feb. 15, 2025

Language: Английский

Citations

1
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany DOI Open Access
Keya Joshi, Stefan Scholz, Michael Maschio

et al.

Journal of Medical Economics, Journal Year: 2023, Volume and Issue: 27(1), P. 39 - 50

Published: Dec. 5, 2023

To assess the potential clinical impact and cost-effectiveness of coronavirus disease 2019 (COVID-19) mRNA vaccines updated for Autumn 2023 in adults aged ≥60 years high-risk persons 30-59 Germany over a 1-year analytic time horizon (September 2023-August 2024).A compartmental Susceptible-Exposed-Infected-Recovered model was adapted to German market. Numbers symptomatic infections, number COVID-19 related hospitalizations deaths, costs, quality-adjusted life-years (QALYs) gained were calculated using decision tree model. The incremental ratio an Moderna (mRNA-1273.815) vaccine compared no additional vaccination. Potential differences between mRNA-1273.815 Pfizer-BioNTech (XBB.1.5 BNT162b2) vaccines, as well societal return on investment relative vaccination, also examined.Compared autumn campaign is predicted prevent approximately 1,697,900 85,400 hospitalizations, 4,100 deaths. Compared XBB.1.5 BNT162b2 campaign, 90,100 3,500 160 Across both analyses we found be dominant.The can considered cost-effective highly likely provide more benefits save costs Germany, offer high investment.

Language: Английский

Citations

12
Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine DOI Creative Commons
Michele Kohli, Michael Maschio, Amy Lee

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(9), P. 2282 - 2289

Published: Feb. 29, 2024

The study objective was to estimate the incidence of COVID-19 infection, hospitalization, and deaths in Japan from September 2023 August 2024 potential impact a monovalent XBB.1.5 variant–adapted Fall vaccine (modified version: XBB monovalent) for adults aged ≥18 years on these outcomes. A previously developed Susceptible-Exposed-Infected-Recovered model United States (US) adapted Japan. numbers symptomatic infections, COVID-19–related hospitalizations, were calculated. Given differences vaccination coverage, masking practices social mixing patterns between US Japan, all inputs updated reflect Japanese context. Vaccine effectiveness (VE) values are hypothetical, but predicted based existing VE bivalent BA.4/BA.5 boosters against VERSUS test-negative case-control study. Sensitivity analyses performed. base case predicts overall that there will be approximately 35.2 million 690,000 62,000 2024. If an is offered 18 older 2023, 7.3 275,000 hospitalizations 26,000 prevented. vaccines only given those 65 older, 2.9 180,000 19,000 analysis results suggest prevented most sensitive initial infection waning rate associated with infection. Symptomatic infections waning. Results would reduce total deaths.

Language: Английский

Citations

4
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan DOI Creative Commons

Kelly Fust,

Keya Joshi, Ekkehard Beck

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(4), P. 434 - 434

Published: April 18, 2024

This analysis estimates the economic and clinical impact of a Moderna updated COVID-19 mRNA Fall 2023 vaccine for adults ≥18 years in Japan. A previously developed Susceptible-Exposed-Infected-Recovered (SEIR) model with one-year analytic time horizon (September 2023–August 2024) consequences decision tree were used to estimate symptomatic infections, related hospitalizations, deaths, quality-adjusted life (QALYs), costs, incremental cost-effectiveness ratio (ICER) versus no additional vaccination, Pfizer–BioNTech vaccine. The is predicted prevent 7.2 million 272,100 hospitalizations 25,600 deaths In base case (healthcare perspective), ICER was ¥1,300,000/QALY gained ($9400 USD/QALY gained). Sensitivity analyses suggest results are most affected by incidence, initial effectiveness (VE), VE waning against infection. Assuming relative between both bivalent vaccines apply vaccines, suggests version will an 1,100,000 27,100 2600 compared expected be highly cost-effective at ¥5 willingness-to-pay threshold across wide range scenarios.

Language: Английский

Citations

4
Are Updated COVID-19 Vaccines Still Relevant for all Adult Age Groups? An Economic Evaluation of the Monovalent XBB.1.5 Vaccine in Australia. DOI Creative Commons
Charles Okafor, Syed Afroz Keramat, Namal N. Balasooriya

et al.

Value in Health, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Cost-effectiveness of routine COVID-19 adult vaccination programmes in England DOI Creative Commons
Matt J. Keeling, Edward M. Hill, Stavros Petrou

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 53, P. 126948 - 126948

Published: March 1, 2025

In England, and many other countries, immunity to SARS-CoV-2 infection COVID-19 disease is highly heterogeneous. Immunity has been acquired through natural infection, primary booster vaccination, while protection lost waning viral mutation. During the height of pandemic in main aim was rapidly protect population large supplies vaccine were pre-purchased, eliminating need for cost-effective calculations. As we move an era where majority infections cause relatively mild disease, stocks be re-purchased, it important consider cost-effectiveness economic value vaccination programmes. Here using data from 2023 2024 England on hospital admissions, ICU admissions deaths, coupled with bespoke health costs, willingness pay threshold vaccines different age risk groups. Willingness thresholds vary less than £1 younger age-groups without any factors, over £100 older comorbidities that place them at risk. This extreme non-linear dependence age, means despite method estimating effectiveness, there considerable qualitative agreement threshold, therefore which ages vaccinate. The historic offer those 65 autumn programme 75 spring programme, aligns our cost- effective pre-purchased when only cost administration. However, future programmes, costs are included, age-thresholds slowly increase thereby demonstrating continued importance protecting eldest most vulnerable population.

Language: Английский

Citations

0
Kosteneffizienz von Impfungen: Über die Komplexität gesundheitsökonomischer Analysen zur Influenza‑, SARS-CoV-2- und RSV-Impfung DOI Creative Commons
Peter Klimek

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Zusammenfassung Die Frage nach der Kosteneffektivität medizinischer Interventionen ist eine zentralen Fragen Gesundheitsökonomie. Dieses narrative Review untersucht die von Impfungen gegen Influenza, SARS-CoV‑2 und das respiratorische Synzytial-Virus (RSV) unter Berücksichtigung aktueller gesundheitsökonomischer Analysen. jährliche Influenza-Impfung Auffrischungsimpfung in den Jahren 2023 2024 erweisen sich, insbesondere Hochrisikogruppen, als kosteneffektiv teilweise sogar kostensparend. Für RSV-Impfung, zugelassen wurde, weniger klar. Sie hängt stark Altersgruppe Bereitschaft ab, für ein gewonnenes qualitätsadjustiertes Lebensjahr (QALY) zu zahlen. Analyse zeigt, dass Bewertung erhebliche Datenmenge erfordert. Modellrechnungen müssen neben direkten Schutzwirkungen auch indirekte Effekte, wie Reduzierung Übertragungen Bevölkerung bei höheren Impfraten, berücksichtigen. Sensitivitätsanalysen verdeutlichen, Faktoren Impfstoffkosten, Effektivität Krankheitsinzidenz entscheidenden Einfluss auf haben können. Eine größten Herausforderungen gesundheitsökonomischen Analysen Fragmentierung Gesundheitsdaten vielen Ländern, was umfassende präzise Bewertungen erschwert. Initiativen europäische Gesundheitsdatenraum könnten hier Abhilfe schaffen evidenzbasierte Entscheidungsfindung Gesundheitspolitik unterstützen. Insgesamt bleibt abhängig zahlreichen Faktoren, wobei SARS-CoV-2- Influenza-Impfungen betrachteten Szenarien positive erhalten.

Citations

0
A response to: A letter to the editor in response to: Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults DOI
Ekkehard Beck,

Mihaela Georgieva,

Nicolas Van de Velde

et al.

Current Medical Research and Opinion, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 5

Published: May 15, 2025

Language: Английский

Citations

0
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France DOI Open Access
Amy S. Lee, Benjamin Davido, Ekkehard Beck

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: March 15, 2024

ABSTRACT An economic evaluation was conducted to predict the and clinical burden of vaccinating immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines in Fall 2023 Spring 2024 versus BNT162b2 France. The number symptomatic infections, hospitalizations, deaths, long COVID cases, costs quality-adjusted life (QALYs) estimated using a static decision-analytic model. Predicted vaccine effectiveness (VE) were based on real-world data from prior versions, suggesting higher protection against infection hospitalization vaccines. VE estimates combined incidence probability severe outcomes. Uncertainty surrounding VE, coverage, incidence, mortality rates, QALYs tested sensitivity analyses. is predicted prevent an additional 3,882 357 81 326 cases when compared 230,000 IC individuals. This translates €10.1 million cost-savings societal perspective 645 saved. Results consistent across all analyses most sensitive variations coverage. These findings highlight importance increasing ability induce levels formulations this vulnerable population.

Language: Английский

Citations

3